<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04577300</url>
  </required_header>
  <id_info>
    <org_study_id>56950</org_study_id>
    <nct_id>NCT04577300</nct_id>
  </id_info>
  <brief_title>Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma</brief_title>
  <official_title>A Randomized, Sham Controlled, Masked Phase II Study to Evaluate the Safety and Efficacy of Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for the Treatment of Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety and efficacy over 24 months of dual NT-501 CNTF encapsulated cell&#xD;
      therapy (ECT) on visual impairment related to glaucoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, sham controlled, masked trial of up to 30 eyes will be recruited into the&#xD;
      study. Participants with a qualifying study eye will be randomized after screening and&#xD;
      baseline evaluations to receive 2 NT-501 ECT implants in the study eye (20 eyes), 1 NT-501&#xD;
      ECT implant (5 eyes) or a sham surgery (control arm; 5 eyes). No explant will be required. An&#xD;
      examination for safety will occur one day and one week following implant and periodically&#xD;
      thereafter for 24 months post-implant. Patients in the control arm may be offered 2 NT-501&#xD;
      ECT implants after the 12-month post-operative follow-up visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Field MD at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in visual field through 12 months as assessed by Mean Deviation (MD).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Field Index at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in visual field through 12 months as assessed by Visual Field Index (VFI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Field PLR at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Change from baseline in visual field pointwise linear regression (PLR) through 12 months.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Dual Implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two NT-501 devices will be implanted in the study eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One NT-501 device will be implanted in the study eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Implantation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>No NT-501 devices will be implanted in the study eye.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NT-501</intervention_name>
    <description>Implant of Neurotech NT-501 device(s)</description>
    <arm_group_label>Dual Implantation</arm_group_label>
    <arm_group_label>Single Implantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham comparator</intervention_name>
    <description>Sham implantation</description>
    <arm_group_label>Sham Implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participant must be medically able to undergo the testing required in the schedule of&#xD;
             events (SOE).&#xD;
&#xD;
          2. Participant's clinical diagnosis must be consistent with glaucoma characterized by the&#xD;
             following features: Mean deviation (MD) of -3 to -20 dB on Humphrey Visual Field 24-2&#xD;
             testing and two visual field tests of adequate quality with a maximum VFI variability&#xD;
             of Â± 10%&#xD;
&#xD;
          3. Residual visual field preservation including best-corrected visual acuity (BCVA)&#xD;
             better than 20/200 in either eye.&#xD;
&#xD;
          4. Participant's eye pressure must be clinically stable, with IOP &lt;21.&#xD;
&#xD;
          5. If a participant has two eyes meeting study criteria, the worse eye as determined by&#xD;
             visual field index (VFI) or patient preference, will be deemed includable. If both&#xD;
             eyes qualify and have the same VFI, a randomization procedure will assign one eye to&#xD;
             the study.&#xD;
&#xD;
          6. Participant must understand and sign the informed consent. If the participant's vision&#xD;
             is impaired to the point where he/she cannot read the informed consent document, the&#xD;
             document will be read to the participant in its entirety.&#xD;
&#xD;
          7. Females of childbearing potential must agree to use an effective form of birth&#xD;
             control.&#xD;
&#xD;
          8. Participant must be determined by the presurgical anesthesia or medical team to be fit&#xD;
             for ophthalmic surgery for the NT-501 ECT implant insertion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participant is unable to comply with study procedures or followup visits.&#xD;
&#xD;
          2. Participant has other optic nerve or retinal degenerative disease causing vision loss,&#xD;
             irrespective of whether it is currently treated or untreated.&#xD;
&#xD;
          3. Participant is likely to be offered glaucoma surgery in the study eye within 6 months&#xD;
             of screening.&#xD;
&#xD;
          4. Participant has cataract-associated vision loss to less than 20/40.&#xD;
&#xD;
          5. Participant has a history of ocular herpes zoster.&#xD;
&#xD;
          6. Participant has a requirement of acyclovir and/or related products during study&#xD;
             duration. To be eligible for this study, the participant must discontinue use of these&#xD;
             products prior to enrollment and must not continue with the products until after they&#xD;
             have completed the study.&#xD;
&#xD;
          7. Participant has evidence of corneal opacification or lack of optical clarity.&#xD;
&#xD;
          8. Participant has uveitis or other ocular inflammatory disease.&#xD;
&#xD;
          9. Participant is receiving systemic steroids or other immunosuppressive medications.&#xD;
&#xD;
         10. Participant has diabetic macular edema and/or diabetic retinopathy.&#xD;
&#xD;
         11. Participant has myopic degeneration.&#xD;
&#xD;
         12. Participant is currently participating in or has within the last 3 months participated&#xD;
             in any other clinical trial of a drug by ocular (if in the study eye) or systemic&#xD;
             administration.&#xD;
&#xD;
         13. Participant is pregnant or lactating.&#xD;
&#xD;
         14. Participant is on chemotherapy.&#xD;
&#xD;
         15. Participant has a history of malignancy other than basal cell carcinoma, unless it was&#xD;
             treated successfully 2 years prior to inclusion in the trial.&#xD;
&#xD;
         16. Participant has, in the opinion of the investigator, any physical or mental condition&#xD;
             that would increase the risk of participation in the study or may interfere with the&#xD;
             study procedures, evaluations and outcome assessments.&#xD;
&#xD;
         17. Any intraocular surgery of the study eye within 12 weeks prior to the screening visit&#xD;
&#xD;
         18. History of use of drugs with known retinal toxicity, at retinotoxic doses.&#xD;
&#xD;
         19. Patient has a history of multiple sclerosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey L Goldberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mariana Nunez, MD</last_name>
    <phone>6504977846</phone>
    <email>mnunez@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Byers Eye Institute at Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariana Nunez</last_name>
      <phone>650-497-7846</phone>
      <email>mnunez@stanford.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 25, 2020</study_first_submitted>
  <study_first_submitted_qc>September 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2020</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Jeffrey L Goldberg</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

